FOR IMMEDIATE DISTRIBUTION
SBH Sciences and Reinnervate are offering Alvetex® introductory 3D tumor cell screening services
(Natick, MA, USA) October 25, 2013. SBH Sciences (Natick, MA) has partner with Reinnervate Ltd (Sedgefield, UK) and offering an introductory services for screening novel anti-cancer drugs using 3D tumour cell culture.
SBH Sciences an innovative pre-clinical oncology and inflammation-focused contract research organization and 3D cell culture company Reinnervate Ltd announced today partnerships to offer 3D tumour cell screening services. Similarly, Reinnervate also sign partnership with Oncotest GmbH (Freiburg, Germany). Both CRO companies will offer a new service for clients wishing to try out cancer 3D cell culture screening for the first time or who wish to evaluate new tumour types in their models.
SBH Sciences now offer an Alvetex® 3D cell culture screening service for Oncology projects. SBH Sciences can offer this service on over 200 human cancer cell lines for lead drug optimization of anti-cancer agents.
The introductory service ranges in price from $1,499 to $2,499 and has the following experimental outline:
- Client picks two cancer cell lines from the available panel (over 200 tumour cell lines are available. Click here for more information.)
- Client provides up to 2 test compounds or specifies two commercially available drugs to be used
- CRO's include one positive control cell line and one positive control compound
- All 3 compounds are tested on the specified 3D tumour cells cultured in Alvetex® 96 3D cell culture plates
- A dose response experiment with ten concentrations in duplicates will be performed using the Promega Cell Titer-Glo® assay
- CRO provides a comprehensive data report with IC50 values and a follow-up telephone conference
- Comparison of 2D and 3D tumour cell responses can be provided (depending on service chosen)
These new introductory 3D tumour cell services will allow more scientists to explore the differences in drug response between 2D and 3D cultured tumour cells' said Richard Rowling, Commercial Director at Reinnervate Ltd. 'These services have been priced at a level which should be affordable for most groups that have not yet had the time to explore the improved biological relevance offered by 3D cell culture systems' he added.
Marcus Rothe, Project Manager at Oncotest commented, 'We have been using Alvetex® 96 3D cell culture plates for some time now and are keen to help as many clients as possible explore the potential benefits of testing new oncology drugs on 3D tumour cells. There is an increasing body of scientific data that shows how tumour cells cultured as monolayers are a poor proxy for the in vivo situation.'
SBH Sciences President and CSO, Raphael Nir said, 'We are pleased to add another innovative service to our services list. We have a panel of over 200 different human tumour cell lines and look forward to helping our clients evaluate 3D tumour cell screening and compare the differences in drug response between 2D and 3D cell culture systems using Alvetex ® technology'.
For more information or to obtain a quote, please e-mail email@example.com or Richard.firstname.lastname@example.org .
About SBH Sciences
SBH Sciences is an innovative pre-clinical contract research organization, located in Natick, Massachusetts. SBH Sciences has been chosen by over 100 biotechnology and pharmaceutical companies for their service needs since 1997. SBH is also the leader of a network of specialized technology partners and provides incubator-style support to startup companies.
SBH Science's unique in-vitro lead drug optimization, cytokines production and cell-based assays, multiplex biomarker analysis and customized biological production including glycosyltransferases and monoclonal antibodies enhance discovery and bio-pharmaceutical development mainly in oncology and inflammation research and assisted its customers to reach their clinical development goals.
About Reinnervate Ltd
Reinnervate is an innovative life sciences company dedicated to making routine 3D cell culture a reality for researchers in academia and in the pharmaceutical and related industries.
Reinnervate was founded in 2002 based on the pioneering research of Professor Stefan Przyborski and his lab at Durham University, UK, and is funded by NorthStar Equity Investors (NSEI), management and private investors.
Alvetex®Scaffold is a unique polystyrene material that provides a robust and inert scaffold for cells to grow and form complex 3D structures in vitro, mimicking the normal growth and formation of tissues in the body. Reinnervate has extensively tested and validated Alvetex®Scaffold with a large number of cell types, including liver, skin, cancer and stem cells, all of which have important applications in basic research into cell development, disease modelling and drug safety screening.
Alvetex®Scaffold has been launched globally in several formats: a 12-well culture plate, 24-well culture plate, 96 well plate, 6-well and 12-well inserts. These formats enable scientists to construct different 3D cell culture models and assays. These include screening of novel drugs / drug combinations on 3D culture and co-culture models, co-culture to study cell-cell or cell-matrix interactions, the growth of cells at the air-liquid interface and the long-term culture of cells. Visit www.reinnervate.com for a full list of applications.
Alvetex®Scaffold was voted as one of the top 100 innovative products of 2011 at the R&D 100 awards and was named among the winners of The Scientist magazine's "Top 10 Life Science Innovations of 2010".
More on 3D tumour cell culture- http://reinnervate.com/cancer-research-goes-3d/